Why Is Pacific Biosciences Stock Up ~6.2% Today?
Today, Pacific Biosciences of California (PACB) is trading at $5.16 per share, up ~6.17% from yesterday’s close of $4.86.
Vectra DA Could Be Solid Growth Driver for Myriad Genetics in 2018
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) Vectra DA test reported revenues close to $16 million.
Myriad Genetics Saw Positive Results from GeneSight Trial
Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.
Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.
BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication
On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).
IBB Holdings: How Are Their Moving Averages Trending?
The iShares Nasdaq Biotechnology ETF (IBB) has 189 stocks in its portfolio. As of June 6, 2016, 87% of IBB’s stocks were trading above their 20-day moving averages.
What Are IBB’s Holdings’ Moving Averages?
On May 27, 2016, 17% of the iShares Nasdaq Biotechnology ETF’s (IBB) stocks were trading above their 20-day moving averages.
Grifols Maintains Its Dividend Payout at 40%
Grifols (GRFS) outperformed other international securities within IBB with a return of 8.5% for the week ending May 27 as it announced a dividend payment.
Options for Investors in the Vanguard Capital Opportunity Fund
From a purely NAV (net asset value) return standpoint, the Vanguard Capital Opportunity Fund has had a forgettable one-year period until March 18, 2016, as it stood tenth among its peer group.
Dyax Traded above Its 100-Day Moving Average
Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.
IBB ADRs Outperform Benchmark for August 10–17, 2015
The iShares NASDAQ Biotechnology ETF (IBB) has 14 American Depository Receipts (ADR) in its portfolio. These ADRs have a weight of 9.36% and gave an average return of 0.85% for August 10–17, 2015.
Healthcare and Pharmaceuticals Prevail in Stable Market Conditions
The healthcare sector and the pharmaceutical sector underperformed IBB, but outperformed the broader index SPY for the week ending July 31, 2015.
Biotech ETF Provides Exposure to International Stocks
The iShares Nasdaq Biotechnology ETF (IBB) has exposure to 14 international stocks, with a weight of 9.36%. For the week ended July 24, the average return of these shares was -2.13%.
Biogen Stock Fell for the Week Ending July 24
For the week ending July 24, 2015, Biogen (BIIB) stock fell by -25.86%. The stock fell based on the downward revision of its 2015 revenue.